Indiplon-IR capsules regulatory update

NBIX disclosed in its third quarter earnings that it is delaying resubmission of an NDA for indiplon 5 and 10 mg immediate-release (IR)

Read the full 234 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE